Page last updated: 2024-11-01

nu6102 and Neoplasms

nu6102 has been researched along with Neoplasms in 2 studies

NU6102: structure in first source

Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.

Research Excerpts

ExcerptRelevanceReference
"We generate CDKi-resistant cancer cells and find that they have reduced proliferative fitness and stably rewired cell cycle control pathways."1.46Spatial competition constrains resistance to targeted cancer therapy. ( Bacevic, K; Boszonyik, B; Fisher, D; Hochberg, ME; Krasinska, L; Noble, R; Prieto, S; Soffar, A; Vincent, C; Wael Ammar, O, 2017)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Tadesse, S1
Caldon, EC1
Tilley, W1
Wang, S1
Bacevic, K1
Noble, R1
Soffar, A1
Wael Ammar, O1
Boszonyik, B1
Prieto, S1
Vincent, C1
Hochberg, ME1
Krasinska, L1
Fisher, D1

Reviews

1 review available for nu6102 and Neoplasms

ArticleYear
Cyclin-Dependent Kinase 2 Inhibitors in Cancer Therapy: An Update.
    Journal of medicinal chemistry, 2019, 05-09, Volume: 62, Issue:9

    Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Cyclin-Dependent Kinase 2; Drug Design; Hu

2019

Other Studies

1 other study available for nu6102 and Neoplasms

ArticleYear
Spatial competition constrains resistance to targeted cancer therapy.
    Nature communications, 2017, 12-08, Volume: 8, Issue:1

    Topics: Animals; Antineoplastic Agents; Cell Culture Techniques; Cell Cycle; Cell Line, Tumor; Cell Prolifer

2017